A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 354 participants.
Also called NCT07816198
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 354 participants
- Sponsor
- Registry
-
NCT07816198
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07816198. Randomized; double masking; primary purpose treatment. Start 2026-09-30 (anticipated); primary completion 2028-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- AD-233A
- Intervention (Drug)
- AD-233B
- Intervention (Drug)
- AD-233C
- Intervention (Drug)
- AD-233D
- Intervention (Drug)
- AD-233A Placebo
- Intervention (Drug)
- AD-233B Placebo
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct07816198- Content hash
25ba40165541f0009a554ca4c9b35fe0ce42a9626bbc54b4fd95a613545ccde2